"The
Report Fibromyalgia - 5EU Drug Forecast and Market Analysis to 2023
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
The
fibromyalgia market
is relatively new and not yet established. Three drugs currently
dominate the sales across the 7MM and form the core treatment
options; Lyrica, Cymbalta and Savella are all approved in the US
while only the former is approved in Japan. Since these drugs are
also available in the 5EU for other indications, they are prescribed
as off-label therapies. A handful of other genericized products also
provide off-label usage including antidepressants, anti-epileptics,
opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella
can provide an effective treatment regimen, there are ample
opportunities for the development of alternative treatment choices
which can expand the medications available to patients, providing
improvement in efficacy, safety and compliance. By 2023, there will
be four new entrants to the market (Lyrica CR, TNX-102 SL, DS-5565
and TD-9855). These new products will help to drive market growth and
offset some of the patent expiries of the leading brands during the
forecast period. Despite these advancements in the treatment
landscape, fibromyalgia therapeutic sales growth are expected to be
minimal.
GlobalData
estimates that the fibromyalgia market across the 5EU reached sales
of approximately $149.7m in 2013. The EU market is expected to grow
at a slower rate compared with the US, owing to a lack of approved
brands and the fact that only one pipeline product is expected to
enter the fibromyalgia market during the forecast period.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/825701
Scope
-
Overview of Fibromyalgia including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in 5EU including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in 5EU from 2013-2023.
-
Analysis of the impact of key events as well the drivers and
restraints affecting 5EU Fibromyalgia market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Fibromyalgia.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2013-2023 in 5EU.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and
Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 12
3.2 Classification 16
3.3 Symptoms 16
3.4 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis and Treatment
Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and
Leading Prescribed Drugs 20
4.1.3 Clinical Practice 22
4.2 France 24
4.3 Germany 25
4.4 Italy 27
4.5 Spain 29
4.6 UK 31
5 Competitive Assessment 34
5.1 Overview 34
5.2 Product Profiles 35
5.2.1 Cymbalta (duloxetine) 35
5.2.2 Savella (milnacipran) 39
5.2.3 Lyrica (pregabalin) 44
5.2.4 Neurontin (gabapentin) 49
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment